Austar Lifesciences Ltd. (HK:6118)
:6118
Want to see HK:6118 full AI Analyst Report?
6118 Stock Chart & Stats
HK$0.89
-HK$0.02(-3.39%)
At close: 4:00 PM EST
HK$0.89
-HK$0.02(-3.39%)
Day’s Range― - ―
52-Week RangeHK$0.65 - HK$1.97
Previous CloseN/A
Volume4.00K
Average Volume (3M)695.30K
Market Cap
HK$415.19M
Enterprise ValueHK$423.01M
Total Cash (Recent Filing)HK$276.59M
Total Debt (Recent Filing)HK$343.82M
Price to Earnings (P/E)11.8
Beta0.96
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding512,582,030
10 Day Avg. Volume1,360,300
30 Day Avg. Volume695,300
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.49
Price to Sales (P/S)0.26
P/FCF Ratio4.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved LeverageDeleveraging to a ~0.42 D/E from ~0.64 materially lowers financial risk and interest burden, improving solvency and funding optionality. This stronger capital structure supports investment, working-capital flexibility and resilience over the next several quarters.
Positive Cash GenerationRe-established operating cash flow (~128.2M) and solid free cash flow (~99.7M) provide internal funding for capex, R&D and debt reduction. Sustainable cash conversion underpins long-term financial flexibility and lowers dependency on external financing if maintained.
Earnings RecoveryReturn to positive net income from prior-year loss signals operational stabilization and execution on cost or revenue initiatives. A consistent earnings base is a prerequisite for margin recovery, reinvestment and durable shareholder returns if trends continue.
Bears Say
Thin Net MarginsVery low net margins constrain retained earnings and limit the company's ability to absorb cost inflation or pricing pressure. Persistently thin profitability reduces reinvestment capacity and makes growth outcomes highly sensitive to small revenue or cost swings.
Choppy Revenue TrendsIrregular top-line performance undermines forecasting and investment planning. Fluctuating revenue suggests demand or product-mix volatility, which hampers the firm's ability to scale operations and deliver consistent margin expansion over the medium term.
Volatile Historical Cash FlowPrior multi-year episodes of negative OCF and FCF indicate cash generation can be cyclical and unreliable. That history raises execution risk: recent positive cash flow must be sustained to secure investments, service debt and support strategic initiatives.
Austar Lifesciences Ltd. News
6118 FAQ
What was Austar Lifesciences Ltd.’s price range in the past 12 months?
Austar Lifesciences Ltd. lowest stock price was HK$0.65 and its highest was HK$1.97 in the past 12 months.
What is Austar Lifesciences Ltd.’s market cap?
Austar Lifesciences Ltd.’s market cap is HK$415.19M.
When is Austar Lifesciences Ltd.’s upcoming earnings report date?
Austar Lifesciences Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 101 days.
How were Austar Lifesciences Ltd.’s earnings last quarter?
Austar Lifesciences Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.019 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.019.
Is Austar Lifesciences Ltd. overvalued?
According to Wall Street analysts Austar Lifesciences Ltd.’s price is currently Overvalued.
Does Austar Lifesciences Ltd. pay dividends?
Austar Lifesciences Ltd. pays a Notavailable dividend of HK$0.05 which represents an annual dividend yield of N/A. See more information on Austar Lifesciences Ltd. dividends here
What is Austar Lifesciences Ltd.’s EPS estimate?
Austar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Austar Lifesciences Ltd. have?
Austar Lifesciences Ltd. has 512,582,030 shares outstanding.
What happened to Austar Lifesciences Ltd.’s price movement after its last earnings report?
Austar Lifesciences Ltd. reported an EPS of HK$0.019 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Austar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in HK:6118
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Austar Lifesciences Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.50%
12-Months-Change
Fundamentals
Return on Equity
4.12%
Trailing 12-Months
Asset Growth
6.89%
Trailing 12-Months
Company Description
Austar Lifesciences Ltd.
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.
Technical Analysis
Vincent Medical Holdings Limited
―
Suzhou Basecare Medical Corp. Ltd. Class H
―
Broncus Holding Corp.
―
Yestar Healthcare Holdings Co Ltd
―
Venus Medtech (Hangzhou), Inc. Class H
―